Alfasigma, Francesco Balestrieri new CEO

Change at the top of Alfasigma. The current CEO Pier Vincenzo Colli has decided to leave the company at the end of October, announces the pharmaceutical company, informing at the same time that Francesco Balestrieri will be appointed new CEO starting from 1 November. “I express to Dr. Colli all our gratitude for the continuous commitment, personal dedication and professional passion constantly shown during this long and intense period, wishing him the best for his future”, declares Stefano Golinelli, president of Alfasigma. “I am sure – he adds – that Dr. Balestrieri will be able to successfully guide our ambitious development plan and implement the growth strategies for the next few years, accelerating the transformation process already started by Alfasigma”. Colli – a note recalls – joined Alfa Wassermann in 2013 as general manager, and then became CEO and CEO of Alfasigma in 2018, after the merger with Sigma-tau. Balestrieri, 52, has a proven track record in the pharmaceutical industry, having held roles of increasing complexity at national, regional and global levels. In his career at Novartis, where he spent more than 20 years, he worked in various business areas, from specialty and branded drugs, to equivalent medicines and self-medication products, managing executive positions of primary responsibility in Europe, North America and Asia.